Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives.Haematologica. 2008; 93: 1769-1772
Survival for older patients with acute myeloid leukemia: a population-based study.Haematologica. 2012; 97: 1916-1924
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States.Blood Adv. 2020; 4: 2192-2201
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.Leukemia. 2021; 36: 913-922https://doi.org/10.1038/s41375-021-01425-9
Clinical outcome of older adults with acute myeloid leukemia: an analysis of a large tertiary referral center over two decades.J Geriatr Oncol. 2021; 12: 540-549
Health-related quality of life and treatment of older adults with acute myeloid leukemia: a young international society of geriatric oncology review paper.Curr Hematol Malig Rep. 2019; 14: 523-535
Beliefs about advanced cancer curability in older patients, their caregivers, and oncologists.Oncologist. 2019; 24: e292-e302
- Derissen E.J.
- Beijnen J.H.
- Schellens J.H.
Concise drug review: azacitidine and decitabine.Oncologist. 2013; 18: 619-624
Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.Pharmacotherapy. 2013; 33: 1341-1352
Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines.Cancer Res. 2009; 69: 8127-8132
A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.PLoS One. 2010; 5e9001
The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.Cell Commun Signal. 2017; 15: 13
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.Oncotarget. 2014; 5: 587-598
Demethylation and up-regulation of an oncogene after hypomethylating therapy.N Engl J Med. 2022; 386: 1998-2010
Oral azacitidine (CC-486) for the treatment of myeloid malignancies.Clin Lymphoma Myeloma Leuk. 2022; 22: 236-250https://doi.org/10.1016/j.clml.2021.09.021
Decitabine/cedazuridine: first approval.Drugs. 2020; 80: 1373-1378
Clinical update on hypomethylating agents.Int J Hematol. 2019; 110: 161-169
Results of astral-1 study, a phase 3 randomized trial of guadecitabine (G) vs treatment choice (TC) in treatment naïve acute myeloid leukemia (TN-AML) not eligible for intensive chemotherapy (IC): S879.HemaSphere. 2019; 3: 394-395
Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis.Exp Hematol Oncol. 2020; 9: 3
Use of azacitidine or decitabine for the up-front setting in acute myeloid leukaemia: a systematic review and meta-analysis.Cancers (Basel). 2021; 13
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.Blood. 2022; 140: 285-289
Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey.Am J Kidney Dis. 2003; 41: 1-12
A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010.Kidney Int. 2015; 88: 950-957
A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous azacitidine and its pharmacokinetics in patients with severe renal impairment.Pharmacotherapy. 2014; 34: 440-451
Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment.Leuk Res. 2013; 37: 889-893
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.Clin Lymphoma Myeloma Leuk. 2010; 10: 205-210
A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine.J Oncol Pharm Pract. 2018; 24: 290-298
- Ham J.C.
- Hoogendijk-van den Akker J.M.
- Verdonck L.F.
A hemodialysis patient with higher-risk myelodysplastic syndrome treated with standard-dose azacitidine.Leuk Lymphoma. 2012; 53: 2521-2522
Azacitidine is removed effectively by hemodialysis.Leuk Lymphoma. 2021; 62: 743-745
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.Blood. 2015; 126: 291-299
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.J Clin Oncol. 2012; 30: 2670-2677
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.Cancer. 2021; 127: 2003-2014
Azacitidine for front-line therapy of patients with AML: reproducible efficacy established by direct comparison of international phase 3 trial data with registry data from the Austrian azacitidine registry of the AGMT study group.Int J Mol Sci. 2017; 18
Response rates as predictors of overall survival: a meta-analysis of acute myeloid leukemia trials.J Cancer. 2017; 8: 1562-1567
Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study.Leuk Lymphoma. 2015; 56: 1033-1042
Deficiency of current acute myeloid leukemia (AML) response criteria to predict response to hypomethylating agent therapy: the value of long-lasting stable disease.Blood. 2016; 128: 2799https://doi.org/10.1182/blood.V128.22.2799.2799
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian azacitidine registry of the AGMT-study group.Ann Hematol. 2014; 93: 1825-1838
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Blood. 2017; 129: 424-447
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.Leukemia. 2021; 35: 1873-1889
5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis.Clin Cancer Res. 2020; 26: 3371-3383
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.Blood. 2019; 133: 7-17
Azacitidine and venetoclax in previously untreated acute myeloid leukemia.N Engl J Med. 2020; 383: 617-629
Impact of venetoclax and azacitidine in treatment-naïve patients with acute myeloid leukemia and IDH1/2 mutations.Clin Cancer Res. 2022; 28: 2753-2761https://doi.org/10.1158/1078-0432.CCR-21-3467
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.Blood Adv. 2020; 4: 1311-1320
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study.Am J Hematol. 2021; 96: 208-217
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.Nat Med. 2015; 21: 178-184
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.Cancer. 2021; 127: 3541-3551
Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine.Clin Cancer Res. 2022; https://doi.org/10.1158/1078-0432.CCR-22-1183
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.Blood. 2020; 135: 791-803
Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.Am J Hematol. 2021; 96: E59-E63
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Blood. 2017; 130: 722-731
Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML.N Engl J Med. 2018; 378: 2386-2398
2-Hydroxyglutarate in acute myeloid leukemia: a journey from pathogenesis to therapies.Biomedicines. 2022; 10
Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia.N Engl J Med. 2022; 386: 1519-1531
Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101.Blood Adv. 2022; 6: 3812-3820
Toward consensus on geriatric assessment in AML.Blood. 2022; 139: 1605-1606
Time at home among older adults with acute myeloid leukemia based on treatment intensity: a SEER-medicare analysis.J Clin Oncol. 2022; 40: 6586
Time spent at home among older adults with AML treated with hypomethylating agents and venetoclax.Blood. 2021; 138: 281
Azacitidine and venetoclax in previously untreated acute myeloid leukemia.N Engl J Med. 2020; 383: 617-629
The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.Leukemia. 2016; 30: 1025-1032
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.Blood. 2022; 140: 1845-1857https://doi.org/10.1182/blood.2021014586
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.Haematologica. 2021; 106: 2121-2130
A phase II study of midostaurin and 5-azacitidine for untreated elderly and unfit patients with FLT3 wild-type acute myelogenous leukemia.Clin Lymphoma Myeloma Leuk. 2020; 20 (): 226-233
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.Blood Cancer J. 2021; 11: 25
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.Lancet Oncol. 2021; 22: 1597-1608
Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia.J Clin Oncol. 2021; 39: 57-65
Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes.Cells. 2022; 11
Intergroup LEAP trial (S1612): a randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.Am J Hematol. 2018; 93: E49-e52
Accrual barriers and detection of early toxicity signal in older less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) in the SWOG 1612 platform randomized phase II/III clinical trial.Blood. 2019; 134: 3905
Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies.Front Oncol. 2019; 9: 1380
Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia.Blood. 2018; 132: 2729
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: phase Ib results.J Clin Oncol. 2020; 38: 7507
AML-196: the first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results.Clin Lymphoma Myeloma Leuk. 2021; 21: S290
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.Br J Haematol. 2022; 196: 368-373
Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature.Clin Cancer Res. 2017; 23: 6430-6440
Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study.Leuk Lymphoma. 2020; 61: 387-396
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.Blood. 2018; 132: 1125-1133
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.Blood. 2018; 131: 1415-1424
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.Leukemia. 2021; 35: 2119-2124
A phase I/II trial of the combination of azacitidine and gemtuzumab ozogamicin for treatment of relapsed acute myeloid leukemia.Clin Lymphoma Myeloma Leuk. 2018; 18: 346-352.e5
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).Blood Adv. 2018; 2: 3608-3617
Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the groupe francophone des myélodysplasies (GFM).J Clin Oncol. 2021; 39: 1575-1583
Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission.N Engl J Med. 2020; 383: 2526-2537
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.Haematologica. 2021; 106: 3240-3244
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.J Hematol Oncol. 2021; 14: 133
Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status.Blood. 2022; 139: 2145-2155https://doi.org/10.1182/blood.2021013404
Maintenance decitabine (DAC) improves disease-free (DFS) and overall survival (OS) after intensive therapy for acute myeloid leukemia (AML) in older adults, particularly in FLT3-ITD-negative patients: ECOG-ACRIN (E-A) E2906 randomized study.Blood. 2019; 134: 115
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.Blood. 2019; 133: 1457-1464
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.Am J Hematol. 2017; 92: 845-850
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.Am J Hematol. 2022; 97: 574-582https://doi.org/10.1002/ajh.26496
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.Blood. 2017; 130: 1156-1164
Allogeneic hematopoietic stem cell transplantation following the use of hypomethylating agents among patients with relapsed or refractory AML: findings from an international retrospective study.Biol Blood Marrow Transplant. 2018; 24: 1754-1758
Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.Ann Hematol. 2020; 100: 1111-1113
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.Haematologica. 2018; 103: e404-e407
Outcomes after stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax-based therapies.Blood. 2019; 134: 264
Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.Br J Haematol. 2021; 196 (): e71-e74https://doi.org/10.1111/bjh.17996
Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia.Biol Blood Marrow Transplant. 2020; 26: e322-e327
Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.Bone Marrow Transplant. 2021; 57: 160-166https://doi.org/10.1038/s41409-021-01476-7
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.Ann Hematol. 2022; 101: 379-387
Outcomes are similar following allogeneic hematopoietic stem cell transplant for newly diagnosed patients who received venetoclax + azacitidine versus intensive chemotherapy.Blood. 2021; 138: 3957
Hypomethylating agents in combination with venetoclax as a bridge to allogeneic transplant in acute myeloid leukemia.Blood. 2020; 136: 32-33
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.Cancer. 2003; 97: 1242-1247
Addition of 10-day decitabine to fludarabine/total body irradiation conditioning is feasible and induces tumor-associated antigen-specific T cell responses.Biol Blood Marrow Transplant. 2016; 22: 1000-1008
A retrospective observation of treatment outcomes using decitabine-combined standard conditioning regimens before transplantation in patients with relapsed or refractory acute myeloid leukemia.Front Oncol. 2021; 11702239
- Bewersdorf J.P.
- Prebet T.
- Gowda L.
Azacitidine maintenance in AML post induction and posttransplant.Curr Opin Hematol. 2022; 29: 84-91https://doi.org/10.1097/MOH.0000000000000700
Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation-a systematic review and meta-analysis.Transplant Cell Ther. 2021; 27 ()
Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial.J Clin Oncol. 2020; 38: 4249-4259
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients.Blood Adv. 2020; 4: 5580-5588
- Ciotti G.
- Marconi G.
- Martinelli G.
Hypomethylating agent-based combination therapies to treat post-hematopoietic stem cell transplant relapse of acute myeloid leukemia.Front Oncol. 2021; 11810387
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.Leukemia. 2012; 26: 381-389
- Webster J.A.
- Luznik L.
- Gojo I.
Treatment of AML relapse after Allo-HCT.Front Oncol. 2021; 11812207
Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy.Leuk Lymphoma. 2020; 61: 3532-3533
Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.Ann Hematol. 2019; 98: 1927-1932
- Chabner B.A.
- Drake J.C.
- Johns D.G.
Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase.Biochem Pharmacol. 1973; 22: 2763-2765
- Gonzalez-Zulueta M.
- et al.
Methylation of the 5’ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.Cancer Res. 1995; 55: 4531-4535
Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML.Blood. 2022; 139: 1646-1658
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.Lancet Haematol. 2019; 6: e29-e37
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).Leuk Lymphoma. 2018; 59: 1113-1120
Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.Br J Haematol. 2020; 190: 461-464
Long-term follow-up of elderly patients with acute myeloid leukemia treated with decitabine: a real-world study of the apulian hematological network.Cancers (Basel). 2022; 14
Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia.Haematologica. 2020; 105: 398-406
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol. 2020; 7: e724-e736
Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia.Am J Hematol. 2018; 93: 1136-1141
Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study.Cancer Discov. 2019; 9: 370-383
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.J Immunother Cancer. 2022; 10
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.Cancer. 2021; 127: 3761-3771
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.Blood Adv. 2020; 4: 4267-4277
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.Cancer. 2018; 124: 325-334
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.Haematologica. 2019; 104: 1565-1571
Hypomethylating agents (HMAs) as salvage therapy in relapsed or refractory AML: an Italian multicentric retrospective study.Biomedicines. 2021; 9
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.Blood Adv. 2018; 2: 923-932
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.Leuk Lymphoma. 2022; : 1-6
Efficacy of venetoclax combined with decitabine-based treatment for heavily pre-treated relapsed or refractory AML patients in a real-world setting.Cancer Manag Res. 2021; 13: 5613-5621
Venetoclax-based regimens for relapsed/refractory acute myeloid leukemia in a real-life setting: a retrospective single-center experience.J Clin Med. 2021; 10
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: a propensity score-matched analysis.Cancer. 2021; 127: 4213-4220
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo clinic series on 86 patients.Am J Hematol. 2020; 95: 1511-1521
Impact of F LT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naïve acute myeloid leukemia.Clin Cancer Res. 2022; 28: 2744-2752https://doi.org/10.1158/1078-0432.CCR-21-3405
Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.Leuk Lymphoma. 2021; 62: 3501-3505
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.Cancer. 2021; 127: 3772-3781